Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Aicardi-Goutieres syndrome (AGS) is an inherited, subacute encephalopathy characterized by the association of basal ganglia calcification, leukodystrophy and cerebrospinal fluid (CSF) lymphocytosis.
Features include very common findings: Spasticity, Global developmental delay, Hypertonia, and Porencephalic cyst and others; and common findings: Microcephaly, Eyelid coloboma, Irritability, and Dry skin and others. 72 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 22 | Spasticity, Global developmental delay, Profound intellectual disability |
In its most characteristic form, Aicardi-Goutires syndrome (AGS) can be considered an early-onset encephalopathy associated with significant intellectual and physical disability.
Aicardi-Goutires syndrome (AGS) should be suspected in individuals with the following clinical, neuroimaging, and supportive laboratory findings [, , , ].
Clinical features
Encephalopathy and/or significant intellectual disability
No approved treatments are currently available for Aicardi-Goutieres syndrome. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for Aicardi-Goutieres syndrome, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for Aicardi-Goutieres syndrome. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
Surveillance includes the following:
Monitoring for signs of diabetes insipidus in the neonatal period
Assessment for glaucoma at least for the first few years of life
Monitoring of the spine for the development of scoliosis
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
142 publications have been identified in PubMed for Aicardi-Goutieres syndrome. Research spans Case Report / Case Series (35%), Basic Science / Preclinical (26%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 49 | 35% |
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 8:44 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Aicardi-Goutieres syndrome
Muscles |
5 |
Extrapyramidal muscular rigidity, Axial hypotonia, Brain atrophy |
Eyes | 5 | Abnormal eye movements (abnormality of eye movement), Glaucoma, Ptosis |
Digestive system | 3 | Hepatosplenomegaly, Elevated circulating hepatic transaminase concentration, Prolonged neonatal jaundice |
Bones and joints | 3 | Joint inflammation (arthritis), Sideways curvature of the spine (scoliosis), Multiple joint contractures |
Heart and blood vessels | 3 | Enlarged heart (cardiomegaly), Thickened heart muscle (hypertrophic cardiomyopathy), Aortic aneurysm |
Lab test results | 2 | Elevated circulating hepatic transaminase concentration, Increased circulating interferon-gamma concentration |
Blood and immune system | 2 | Autoimmunity, Neonatal alloimmune thrombocytopenia |
Hormones | 2 | Diabetes mellitus, Hypothyroidism |
Pregnancy and birth | 2 | Neonatal alloimmune thrombocytopenia, Prolonged neonatal jaundice |
Head and neck | 1 | Microcephaly |
Skin | 1 | Dry skin |
Metabolism | 1 | Unexplained fevers |
Growth and development | 1 | Short stature |
Age of onset: newborn period.
In its most characteristic form, Aicardi-Goutires syndrome (AGS) can be considered an early-onset encephalopathy associated with significant intellectual and physical disability. Pregnancy, delivery, and the neonatal period are normal in approximately 80% of infants with Aicardi-Goutires syndrome (AGS) . However, brain calcifications can be identified in utero and 20% of cases, mainly those caused by biallelic pathogenic variants in TREX1, present at birth with abnormal neurologic findings, hepatosplenomegaly, elevated liver enzymes, and thrombocytopenia, a picture reminiscent of congenital infection. All other affected infants present at variable times after the first few weeks of life, frequently after a period of apparently normal development.
Source: GeneReviews — "Aicardi-Goutires Syndrome"
Acquired microcephaly during the first year of life
Dystonia and spasticity
Sterile pyrexias
Hepatosplenomegaly
Chilblain lesions on the feet, hands, ears, and sometimes more generalized mottling of the skin. See .
Exclusion criteria include the following:
Source: GeneReviews — "Aicardi-Goutires Syndrome"
Calcification of the basal ganglia is a nonspecific finding seen in many diseases. However, in the context of an early-onset encephalopathy, conditions to consider include the following:
TORCH congenital infections are the most common conditions in the differential and the most important to rule out because misdiagnosis would result in erroneous counseling as to risk of recurrence.
Note: Other congenital infections, such as those associated with Zika and HIV, should also be considered in the differential diagnosis.
Source: GeneReviews — "Aicardi-Goutires Syndrome"
Biomarker and diagnostic research for Aicardi-Goutieres syndrome has been reported in the published literature.
Designated
Exclusivity End |
|---|
Designation Status |
|---|
non-covalent competitive cGAS inhibitor | non-covalent competitive cGAS inhibitor | ImmuneSensor Therapeutics | 2024 | — | Designated |
To establish the extent of disease and needs in an individual diagnosed with Aicardi-Goutires syndrome (AGS), the following evaluations are recommended:
Developmental assessment
Assessment of feeding and nutritional status
Ophthalmologic examination
EEG to evaluate for seizures, if suspected
Consultation with a clinical geneticist and/or genetic counselor
The following are appropriate:
Chest physiotherapy and vigorous treatment of respiratory complications
Attention to diet and method of feeding to assure adequate caloric intake
Management of seizures using standard protocols
Surveillance includes the following:
Monitoring for signs of diabetes insipidus in the neonatal period
Assessment for glaucoma at least for the first few years of life
Monitoring of the spine for the development of scoliosis
Monitoring for signs of insulin-dependent diabetes mellitus and hypothyroidism
See for issues related to testing of at-risk relatives for genetic counseling purposes.
Research into the role of immunosuppressive agents in the treatment of AGS is ongoing . Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Corticosteroids can lower the CSF concentration of interferon [PG Barth 2003, personal communication]; the clinical benefit of such t...
Source: GeneReviews — "Aicardi-Goutires Syndrome"
Research into the role of immunosuppressive agents in the treatment of AGS is ongoing . Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "Aicardi-Goutires Syndrome"
1 trial found
Monitoring for signs of insulin-dependent diabetes mellitus and hypothyroidism
Source: GeneReviews — "Aicardi-Goutires Syndrome"
Phenotype severity distribution: 7 very common features, 28 common features.
Estimated prevalence: Unknown (Unknown prevalence).
Laboratory research |
37 |
26% |
Research summaries | 23 | 16% |
Disease patterns and progression | 11 | 8% |
Clinical study results | 8 | 6% |
Testing and diagnosis research | 7 | 5% |
New treatment approaches | 5 | 4% |
Other research | 2 | 1% |
Han VX (2026). [PMID: 42016148](https://pubmed.ncbi.nlm.nih.gov/42016148/). *Clin Transl Immunology*. [Basic Science / Preclinical]
Tsujioka Y (2026). [PMID: 42176059](https://pubmed.ncbi.nlm.nih.gov/42176059/). *Pediatr Radiol*. [Review / Meta-Analysis]
Dale RC (2026). [PMID: 41726773](https://pubmed.ncbi.nlm.nih.gov/41726773/). *Clin Transl Immunology*. [Basic Science / Preclinical]
Lacovich V (2026). [PMID: 40920008](https://pubmed.ncbi.nlm.nih.gov/40920008/). *Brain : a journal of neurology*. [Basic Science / Preclinical]
Yoo H (2026). [PMID: 41855203](https://pubmed.ncbi.nlm.nih.gov/41855203/). *Cell Rep*. [Basic Science / Preclinical]
Wege L (2026). [PMID: 42064048](https://pubmed.ncbi.nlm.nih.gov/42064048/). *Front Immunol*. [Basic Science / Preclinical]
Gonzalez Saez-Diez E (2026). [PMID: 42033272](https://pubmed.ncbi.nlm.nih.gov/42033272/). *Ann Clin Transl Neurol*. [Clinical Trial Publication]
McKinney JE (2026). [PMID: 41587891](https://pubmed.ncbi.nlm.nih.gov/41587891/). *Annual review of pathology*. [Review / Meta-Analysis]
Turan K (2026). [PMID: 41948752](https://pubmed.ncbi.nlm.nih.gov/41948752/). *Clin Case Rep*. [Case Report / Case Series]
Li W (2026). [PMID: 41076779](https://pubmed.ncbi.nlm.nih.gov/41076779/). *European journal of medicinal chemistry*. [Case Report / Case Series]
AI-curated news mentioning Aicardi-Goutieres syndrome
Updated Aug 28, 2026
A large cohort study from the UK Biobank investigates the association between serum uric acid levels, gout, and the incidence of sepsis. The findings contribute to understanding the potential links between these conditions, although specific results and implications require further exploration.
A recent publication discusses disseminated chronic tophaceous gout with multi-tissue involvement, highlighting the complexities of this rare condition. The study provides insights into the clinical manifestations and potential treatment approaches.
Crystalys secures an additional $130 million to advance its gout treatment through late-stage trials. The drug is already approved in several Asian countries but has yet to gain access in the U.S. or Europe.
A study highlights the synergistic effects of the ABCG2 Q141K variant, alcohol consumption, and male sex on gout risk in a Taiwanese cohort. This research contributes to understanding genetic and lifestyle factors influencing gout susceptibility.